Sputnik V registered in countries with total population of over 1.1 billion people

Sputnik V registered in countries with total population of over 1.1 billion people

Moscow, February 25, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that Sputnik V vaccine against coronavirus is now registered in 37 countries with total population of over 1.1 billion people.

To date, Sputnik V had been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras and Guatemala.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“An important milestone today: over 1.1 billion people live in 37 countries, where Sputnik V got emergency authorization. We’ll continue working with Latin America, North America, Europe, Africa, Middle East and Asia to save lives and restore economies. Together we are stronger!”

Sputnik V has a number of key advantages:

·        Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals; it is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.

·        The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.

·        There are no strong allergies caused by Sputnik V.

·        The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

·        The price of Sputnik V is less than $10 per shot, making it affordable around the world.